Lung Cancer Trials Ask AI to find trials
RecruitingNot applicableNCT05502523
Official study title

The Impact of Surgical Technique on Circulating Tumor DNA in Stage I-III Non-Small Cell Lung Cancer

Study summary

This clinical trial compares the effect of pulmonary vein-first surgical technique to pulmonary artery-first surgical technique in decreasing circulating tumor cell deoxyribonucleic acid (ctDNA) in patients with stage I-III non-small cell lung cancer. Pulmonary vein first and pulmonary artery first surgical techniques are standard surgical techniques for the division of the blood vessels during lung resection surgery. Pulmonary vein-first surgical technique may reduce the risk of shedding tumor cells during surgery and influence long term overall survival.

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedPulmonary Artery-First Surgical Technique and Biospecimen Collection

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC) · Early-stage or resectable · Locally advanced

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jan 23, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Recruiting

The study is currently accepting participants.

What kind of study?Not applicable

Interventional

Where is it offered?4 U.S. locations

Locations may change over time.

Who runs it?Thomas Jefferson University

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Not applicable
Sponsor
Thomas Jefferson University
Interventions being studied
Procedure: Pulmonary Artery-First Surgical Technique; Procedure: Biospecimen Collection
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
Disease setting
Early-stage or resectable→Locally advanced→
Treatment approach
Surgery→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Any patients 18 years of age or older with confirmed or suspected early-stage (stage I-III) NSCLC
  • Eligible and scheduled for surgical anatomic lung resection (e.g. lobectomy or segmentectomy) as routine clinical care for their disease
Reasons someone may not be able to joinExclusion criteria
  • Previous cancer diagnosis within 5 years (except ductal carcinoma in situ \[DCIS\] of the breast, superficial bladder cancer, non-melanoma skin primary, other malignancy that does not require treatment).
  • Preoperative chemotherapy, immunotherapy, or radiation therapy
  • Receipt of perioperative blood transfusion

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Abington Memorial HospitalAbington, Pennsylvania
  • Jefferson Health NortheastPhiladelphia, Pennsylvania
  • Thomas Jefferson University HospitalPhiladelphia, Pennsylvania
  • Asplundh Cancer Pavilion at Jefferson HealthWillow Grove, Pennsylvania

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jan 23, 2026. Always confirm current availability with the study team.

View original record ↗